Terns Pharmaceuticals, Inc. (TERN) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Terns Pharmaceuticals, Inc. (TERN) Bundle
Streamline your analysis and improve precision with our (TERN) DCF Calculator! Utilizing up-to-date data from Terns Pharmaceuticals, Inc. and customizable assumptions, this tool empowers you to forecast, evaluate, and assess the value of (TERN) like an expert investor.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | 1.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | -100 | 0 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -35.0 | -36.6 | -49.3 | -59.0 | -102.6 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | -4934.8 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .2 | .4 | .5 | 1.0 | .3 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 51.2 | 100 | 100 | 90.24 | 90.24 | 90.24 | 90.24 | 90.24 |
EBIT | -35.2 | -37.0 | -49.9 | -60.0 | -102.9 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | -4986 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 19.7 | 74.9 | 166.0 | 283.1 | 263.4 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | 12.7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 0 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
Inventories | .0 | 3.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 0 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | 1.6 | .9 | 2.1 | 1.6 | 2.5 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 212.6 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -.9 | -.6 | -.3 | -.3 | -.1 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | -34 | 100 | 100 | -6.8 | -6.8 | -6.8 | -6.8 | -6.8 |
Tax Rate, % | -0.26564 | -0.26564 | -0.26564 | -0.26564 | -0.26564 | -0.26564 | -0.26564 | -0.26564 | -0.26564 | -0.26564 |
EBITAT | -35.2 | -37.8 | -50.4 | -60.3 | -103.1 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -34.3 | -54.4 | -33.3 | -60.1 | -102.0 | -2.5 | .0 | .0 | .0 | .0 |
WACC, % | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 | 5.39 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | -79 | |||||||||
Equity Value | 77 | |||||||||
Diluted Shares Outstanding, MM | 71 | |||||||||
Equity Value Per Share | 1.08 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real TERN financials.
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect Terns Pharmaceuticals’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Terns Financials: Gain access to precise pre-loaded historical data and future forecasts.
- Adjustable Forecast Parameters: Modify editable cells highlighted in yellow, such as WACC, growth rates, and profit margins.
- Automated Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to help visualize your valuation outcomes.
- Designed for All Skill Levels: An easy-to-navigate layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download: Access the ready-to-use Excel file with Terns Pharmaceuticals, Inc. (TERN) financial data.
- Customize: Adjust forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations update in real-time.
- Test Scenarios: Create multiple projections and compare outcomes instantly.
- Make Decisions: Use the valuation results to guide your investment strategy.
Why Choose Terns Pharmaceuticals, Inc. (TERN)?
- Innovative Solutions: Cutting-edge therapies developed to address unmet medical needs.
- Proven Expertise: A team of seasoned professionals with extensive industry experience.
- Commitment to Quality: Rigorous standards ensure the highest level of product integrity.
- Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
- Strong Partnerships: Collaborations with leading organizations to enhance research and development.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Terns Pharmaceuticals stock (TERN).
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Terns Pharmaceuticals (TERN).
- Consultants: Deliver professional valuation insights to clients quickly and accurately, focusing on Terns Pharmaceuticals (TERN).
- Business Owners: Understand how biopharmaceutical companies like Terns Pharmaceuticals are valued to guide your own strategy (TERN).
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Terns Pharmaceuticals (TERN).
What the Template Contains
- Historical Data: Includes Terns Pharmaceuticals’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Terns Pharmaceuticals’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Terns Pharmaceuticals’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.